Brief: Silk Road Medical Announces Post Approval Study For Treatment Of Standard Surgical Risk Patients Using Tcar
15/06/2022 14:11
June 15 (Reuters) - Silk Road Medical Inc SILK.O :
* SILK ROAD MEDICAL ANNOUNCES POST APPROVAL STUDY FOR
TREATMENT OF
STANDARD SURGICAL RISK PATIENTS USING TCAR
* STUDY TARGETS A MAXIMUM ENROLLMENT OF 400 PATIENTS ACROSS
APPROXIMATELY 50 SITES
Source text for Eikon: ID:nGNX2Jm5KL
Further company coverage: SILK.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Silk Road Medical
See all newsBrief: Silk Road Medical Boston Scientific To Be Required To Pay Co Termination Fee Of $69.5 Million If Merger Agreement Terminated Under Certain Circumstances
Boston Scientific to buy Silk Road Medical in $1.16 billion deal (updated)
Brief: Boston Scientific Announces Agreement to Acquire Silk Road Medical
Brief: Silk Road Medical Announces Definitive Agreement To Be Acquired By Boston Scientific
Boston Scientific to buy Silk Road Medical for $1.16 billion